Loading provider…
Loading provider…
Hematology & Oncology Physician in Baltimore, MD
NPI: 1457615270Primary Practice Location
SINAI HOSPITAL OF BALTIMORE
2401 W Belvedere Ave, Baltimore, MD
Primary Employer
Sinai Hospital of Baltimore Inc
lifebridgehealth.org
HQ Phone
Get MBBS Maitri's Phone Numberphone_androidMobile
Get MBBS Maitri's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIN State Medical License
MD State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 87 | 148 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 76 | 224 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 65 | 65 |
| 4 | G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 23 | 28 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 21 | 25 |
Authors: Woollam, Mark, Wang, Luqi, Grocki, Paul, Liu, Shengzhi, Siegel, Amanda P, Kalra, Maitri, Goodpaster, John V, Yokota, Hiroki, Agarwal, Mangilal
Journal: Cancers (Basel)
Publication Date: 2021-03-23
Authors: David Jones, Michael Danso, Cynthia Ma, Sunil Badve, Paula Silverman
Journal: NPJ Breast Cancer
Publication Date: 2021-03-22
Lead Sponsor: Shadia Jalal, MD
Collaborators: Astex Pharmaceuticals, Inc., Indiana University School of Medicine
Intervention / Treatment: DRUG: Carboplatin, DRUG: Guadecitabine
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Quality-of-Life Assessment, OTHER: Usual care disease monitoring, OTHER: Serum Tumor Marker directed disease monitoring, OTHER: Anxiety Questionnaire Administration
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: United States Department of Defense, National Cancer Institute (NCI), Bayer, Canadian Cancer Trials Group
Intervention / Treatment: OTHER: Placebo, DRUG: Aspirin